Humacyte Inc · Q1 2025 earnings

Briefing

Humacyte announced its first quarter 2025 financial results and provided a business update, highlighting the commercial launch of Symvess and strategic cost reductions.

Humacyte reported total revenues of $517,000 for the first quarter of 2025, driven by initial commercial sales of Symvess and a research collaboration. The company achieved a net income of $39.1 million, a significant improvement from a net loss in the prior year, primarily due to a non-cash remeasurement of contingent earnout liability. They also completed a public offering raising $46.7 million in net proceeds and implemented cost reductions to extend their cash runway.

• Humacyte commenced the commercial launch of Symvess in late February 2025, with initial sales to three Level 1 trauma centers.
• The company reported total revenues of $517,000 for Q1 2025, including $147,000 from Symvess sales and $370,000 from a research collaboration.
• Net income for Q1 2025 was $39.1 million, a substantial increase from a net loss of $31.9 million in Q1 2024, largely due to a non-cash remeasurement of contingent earnout liability.
• Humacyte completed a public offering in March 2025, raising $46.7 million in net proceeds, and implemented cost reduction actions expected to save over $50 million in 2025 and 2026.

Headline financials

Revenue & EPS history

Humacyte plans to aggressively expand its commercial launch of Symvess, continue developing its bioengineering pipeline, and pursue regulatory filings for additional indications, while maintaining cost discipline.